Innate Pharma SA announced that an abstract regarding its preclinical asset IPH45, a novel and differentiated topoisomerase I inhibitor Antibody Drug Conjugate targeting Nectin-4, has been selected for oral presentation at the American Association for Cancer Research Annual Meeting 2024, taking place April 5-10 in San Diego, California.
